Eli Lilly & Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative.
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,